Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC7 | O00311 | 2/20 | 0.61 |
| ▸ | DBF4 | Q9UBU7 | 2/20 | 0.61 |
| ▸ | JAK2 | O60674 | 3/20 | 0.54 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.54 |
| ▸ | TTBK1 | Q5TCY1 | 7/20 | 0.51 |
| ▸ | TTBK2 | Q6IQ55 | 7/20 | 0.51 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.50 |
| ▸ | CSF1R | P07333 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | JAK3 | P52333 | 3/20 | 0.42 |
| ▸ | DAPK3 | O43293 | 2/20 | 0.42 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.42 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.42 |
| ▸ | PAK4 | O96013 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6661474 | 0.84 | TRPA1 (0.52) | CDC7DBF4JAK2NOTUMTTBK1 | |
| SCHEMBL26784728 | 0.84 | TTBK1 (0.49) | CDC7DBF4JAK2NOTUMTTBK1 | |
| SCHEMBL26786653 | 0.80 | TTBK1 (0.57) | CDC7DBF4NOTUMTTBK1TTBK2 | |
| SCHEMBL6273375 | 0.78 | TTBK1 (0.52) | CDC7DBF4JAK2NOTUMTTBK1 | |
| SCHEMBL192920 | 0.76 | CDC7 (1.00) | CDC7DBF4JAK2NOTUMTTBK1 | |
| SCHEMBL21218365 | 0.74 | TTBK1 (0.60) | CDC7DBF4JAK2TTBK1TTBK2 | |
| SCHEMBL796397 | 0.73 | LMNA (0.44) | CDC7DBF4JAK2NOTUMLMNA | |
| SCHEMBL5244234 | 0.72 | LMNA (0.56) | LMNAMAPTSMN1; SMN2NPC1ALDH1A1 | |
| SCHEMBL27212829 | 0.72 | KDM1A (0.58) | LMNAMAPTSMN1; SMN2NPC1ALDH1A1 | |
| SCHEMBL17954541 | 0.71 | CDC7 (0.63) | CDC7DBF4JAK2NOTUMTTBK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4662319-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | Integrate Bioscience LLC (US) | 2025-12-17 | — | — | EP | disclosed |
| WO-2024168301-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | FUNCTION ONCOLOGY, INC. (US) | 2024-08-15 | — | — | WO | disclosed |
| US-20190255052-A1 | Inhibitors of E1 Activating Enzymes | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2019-08-22 | — | — | US | disclosed |
| CN-110003216-A | E1 activating enzyme inhibitors | 千禧药品公司 | 2019-07-12 | — | — | CN | disclosed |
| CN-106008512-B | E1 activating enzyme inhibitors | 千禧药品公司 | 2019-03-12 | — | — | CN | disclosed |
| US-20170136024-A1 | INHIBITORS OF E1 ACTIVATING ENZYMES | MILLENNIUM PHARMACEUTICALS, INC. | 2017-05-18 | — | — | US | disclosed |
| CN-106008512-A | INHIBITORS OF E1 ACTIVATING ENZYMES | 千禧药品公司 | 2016-10-12 | — | — | CN | disclosed |
| EP-2402334-B1 | Inhibitors of E1 Activating Enzymes | MILLENNIUM PHARM INC (US) | 2016-06-29 | — | — | EP | disclosed |
| CN-101379061-B | E1 activating enzyme inhibitor | 千禧药品公司 | 2016-06-15 | — | — | CN | disclosed |
| US-20130289037-A1 | INHIBITORS OF E1 ACTIVTING ENZYMES | MILLENNIUM PHARM INC (US) | 2013-10-31 | — | — | US | disclosed |
| US-20130165457-A9 | INHIBITORS OF E1 ACTIVATING ENZYMES | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-06-27 | — | — | US | disclosed |
| US-20120258977-A1 | INHIBITORS OF E1 ACTIVATING ENZYMES | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-10-11 | — | — | US | disclosed |
| US-20120258927-A1 | INHIBITORS OF E1 ACTIVATING ENZYMES | MILLENIUM PHARMACEUTICALS, INC. (US) | 2012-10-11 | — | — | US | disclosed |
| EP-1989206-B1 | INHIBITORS OF E1 ACTIVATING ENZYME | MILLENNIUM PHARM INC (US) | 2012-07-04 | — | — | EP | disclosed |
| US-8207177-B2 | Inhibitors of E1 activating enzymes | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-06-26 | — | — | US | disclosed |
| EP-2402334-A1 | Inhibitors of E1 Activating Enzymes | Millennium Pharmaceuticals, Inc. (US) | 2012-01-04 | — | — | EP | disclosed |
| US-20070191293-A1 | Inhibitors of E1 activating enzymes | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-08-16 | — | — | US | disclosed |
| EP-1444982-A1 | The use of purine derivatives as selective kinase inhibitors | MERCKLE GMBH (DE) | 2004-08-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120258977-A1 | INHIBITORS OF E1 ACTIVATING ENZYMES | ECE1, RNASE1, RCE1 | CDC7 342/4885DBF4 3600/4885JAK2 3421/4885 |
| US-20120258927-A1 | INHIBITORS OF E1 ACTIVATING ENZYMES | ECE1, RNASE1, RCE1 | CDC7 342/4885DBF4 3600/4885JAK2 3421/4885 |
| US-20170136024-A1 | INHIBITORS OF E1 ACTIVATING ENZYMES | ECE1, RNASE1, RCE1 | CDC7 342/4885DBF4 3600/4885JAK2 3421/4885 |
| US-20190255052-A1 | Inhibitors of E1 Activating Enzymes | ECE1, RNASE1, RCE1 | CDC7 342/4885DBF4 3600/4885JAK2 3421/4885 |
| US-20130165457-A9 | INHIBITORS OF E1 ACTIVATING ENZYMES | ECE1, RNASE1, RCE1 | CDC7 342/4885DBF4 3600/4885JAK2 3421/4885 |
| US-20130289037-A1 | INHIBITORS OF E1 ACTIVTING ENZYMES | RNASE1, ECE1, CES1 | CDC7 304/4885DBF4 3355/4885JAK2 3623/4885 |
| US-20070191293-A1 | Inhibitors of E1 activating enzymes | ECE1, RNASE1, RCE1 | CDC7 342/4885DBF4 3600/4885JAK2 3421/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.